A Case of Bullous Dermatitis Induced by Erlotinib

Herein, we report a case of bullous dermatitis that occurred in a 61‐year‐old woman 5 days after beginning therapy with erlotinib for the treatment of stage IV pulmonary adenocarcinoma with metastases at the hypophyseal level. Skin reactions are the most common adverse drug reactions (ADRs) associat...

Full description

Saved in:
Bibliographic Details
Published in:The oncologist (Dayton, Ohio) Ohio), 2009-12, Vol.14 (12), p.1201-1204
Main Authors: Oteri, Alessandro, Cattaneo, Maria Teresa, Filipazzi, Virginio, Ferrario, Sabrina, Gambaro, Anna, Isabella, Luigi, Tosca, Nicoletta, Clementi, Emilio, Radice, Sonia, Piazza, Elena
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Bullous dermatitis
Case report
Dermatitis - etiology
Dermatitis - pathology
Drug Eruptions - etiology
Drug Eruptions - pathology
Erlotinib
Erlotinib Hydrochloride
Female
Humans
Lung Neoplasms - drug therapy
Middle Aged
Protein Kinase Inhibitors - administration & dosage
Protein Kinase Inhibitors - adverse effects
Quinazolines - administration & dosage
Quinazolines - adverse effects
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Receptor, Epidermal Growth Factor - therapeutic use
Skin Diseases, Vesiculobullous - chemically induced
Skin Diseases, Vesiculobullous - drug therapy
Skin toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Herein, we report a case of bullous dermatitis that occurred in a 61‐year‐old woman 5 days after beginning therapy with erlotinib for the treatment of stage IV pulmonary adenocarcinoma with metastases at the hypophyseal level. Skin reactions are the most common adverse drug reactions (ADRs) associated with epidermal growth factor receptor tyrosine kinase (EGFR‐TK) inhibitors, and acneiform rash is the most frequently reported ADR in patients treated with erlotinib. To our knowledge, this is the first case of bullous dermatitis induced by erlotinib. This report highlights the need for additional research in the field of skin toxicity of EGFR‐TK inhibitors. Reported is a case of bullous dermatitis that occurred in a 61‐year‐old woman 5 days after beginning therapy with erlotinib for the treatment of stage IV pulmonary adenocarcinoma with metastases at the hypophyseal level.
ISSN:1083-7159
1549-490X
DOI:10.1634/theoncologist.2009-0118